Free Trial

Achilles Therapeutics Q2 2024 Earnings Report

Achilles Therapeutics logo
$0.98 0.00 (0.00%)
(As of 12/20/2024 05:31 PM ET)

Achilles Therapeutics EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.41
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Achilles Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achilles Therapeutics Announcement Details

Quarter
Q2 2024
Time
TAS

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Achilles Therapeutics Earnings Headlines

This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Achilles Therapeutics reports Q3 EPS (48c) vs. (42c) last year
See More Achilles Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achilles Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achilles Therapeutics and other key companies, straight to your email.

About Achilles Therapeutics

Achilles Therapeutics (NASDAQ:ACHL), a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

View Achilles Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings